Gilead Sciences, Inc. (GILD) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been assigned a consensus rating of “Buy” from the twenty-nine analysts that are presently covering the company, MarketBeat Ratings reports. Twelve equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $79.38.

GILD has been the subject of a number of recent research reports. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 price objective for the company in a report on Tuesday, April 18th. Jefferies Group LLC reissued a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, April 6th. J P Morgan Chase & Co reissued an “overweight” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, April 6th. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a research report on Tuesday, May 2nd. Finally, Barclays PLC reissued an “overweight” rating and set a $85.00 target price (down previously from $90.00) on shares of Gilead Sciences in a research report on Sunday, April 23rd.

WARNING: This report was first published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.thestockobserver.com/2017/06/20/gilead-sciences-inc-gild-given-consensus-recommendation-of-buy-by-analysts-updated.html.

In related news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $214,973,917.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Francis Cogan sold 9,943 shares of Gilead Sciences stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. Following the sale, the director now directly owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. In the last three months, insiders sold 88,276 shares of company stock valued at $5,932,578. Insiders own 1.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in GILD. Aldebaran Financial Inc. increased its stake in shares of Gilead Sciences by 2.5% in the first quarter. Aldebaran Financial Inc. now owns 17,755 shares of the biopharmaceutical company’s stock valued at $1,206,000 after buying an additional 441 shares during the last quarter. TrueNorth Inc. increased its stake in shares of Gilead Sciences by 3.7% in the first quarter. TrueNorth Inc. now owns 9,525 shares of the biopharmaceutical company’s stock valued at $647,000 after buying an additional 338 shares during the last quarter. Perigon Wealth Management LLC increased its stake in shares of Gilead Sciences by 3.5% in the first quarter. Perigon Wealth Management LLC now owns 71,402 shares of the biopharmaceutical company’s stock valued at $4,850,000 after buying an additional 2,407 shares during the last quarter. Piedmont Investment Advisors LLC increased its stake in shares of Gilead Sciences by 0.9% in the first quarter. Piedmont Investment Advisors LLC now owns 282,454 shares of the biopharmaceutical company’s stock valued at $19,184,000 after buying an additional 2,410 shares during the last quarter. Finally, Bedell Frazier Investment Counseling LLC increased its stake in shares of Gilead Sciences by 6.4% in the first quarter. Bedell Frazier Investment Counseling LLC now owns 60,221 shares of the biopharmaceutical company’s stock valued at $4,090,000 after buying an additional 3,631 shares during the last quarter. 73.99% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences (GILD) traded up 0.99% during trading on Tuesday, reaching $65.46. The company had a trading volume of 6,822,409 shares. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $88.85. The firm has a market capitalization of $85.54 billion, a P/E ratio of 6.92 and a beta of 1.20. The company has a 50-day moving average of $65.54 and a 200-day moving average of $69.05. Gilead Sciences also was the recipient of unusually large options trading activity on Monday. Stock investors purchased 22,560 call options on the company. This represents an increase of 103% compared to the typical volume of 11,118 call options.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.18 by $0.02. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. Analysts expect that Gilead Sciences will post $8.20 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 21.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply